SAN DIEGO—The 2017 ACR/ARHP Annual Meeting kicked off on Nov. 4 with a rousing presentation by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID). A terrorist attack on U.S. soil, hurricane, cyberattack and pandemic were the four scenarios played out in late 2016, when NIAID conducted a tabletop… [Read More]
Rheumatologists are already familiar with one mosquito-borne virus, chikungunya, whose presentation mimics arthritis. Now, with its recent spread to Puerto Rico and the Southeastern U.S., Zika, another mosquito-borne virus, has become an international public health concern. Sexual transmission of the virus was recently confirmed, expanding the virus’s threat…... [Read More]
COVID-19 isn’t the only viral infection on the rise across the globe, so is chikungunya, which can cause arthritis-like symptoms and may lead to long-term joint pain.... [Read More]
ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, ACR President Ellen M. Gravallese, MD, chief of the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital, Boston, presented the inaugural ACR Distinguished Global Public Health Award to Anthony S. Fauci, MD, director of the National Institute of Allergy… [Read More]
ACR CONVERGENCE 2020—A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across… [Read More]
Looking back on last year’s ACR/ARP annual meeting, I recall the energy and excitement of attendees as they participated in sessions covering the latest scientific concepts and new directions in our field. In 2019, we piloted a number of innovative ways to modernize and enhance future ACR meetings, with the promise of delivering a transformed… [Read More]
The ACR, on behalf of its more than 7,700 members of the professional rheumatology community, wishes to express strong support for Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic. During… [Read More]
Advocacy efforts on access and workforce issues in Florida are discussed.... [Read More]
NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,… [Read More]
Researchers suggest antiviral therapy is not appropriate for patients with GCA, based on their study findings and related research…... [Read More]